Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine added to bupivacaine TAP block in laparoscopic bariatric surgery
PACTR202208575341765Phase 3Not yet recruiting
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Sep 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in obesity comparing TAP block with plain bupivacaine with TAP block with bupivacaine plus nalbuphine (2 arms). Primary endpoint: Time to first full ambulation. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
nalbuphinebupivacaine
03
Conditions
obesity
Beyond the preview
Go deeper on PACTR202208575341765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202208575341765.